pharmaceuticals

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Immune Pharmaceuticals Shares Are Skyrocketing

Shares of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) saw an incredible gain in Thursday’s session following a key announcement. The company says that it has entered into a letter of intent ...
Read Full Story »

Why One Analyst Is Growing Very Bullish on Life Sciences

Over the past five, 10 and 20 years, the life sciences and bioproduction segments have tended to outperform the S&P 500 more often than not. Considering the exposure to biopharma ...
Read Full Story »

Arena Pharmaceuticals Sinks After Announcing Secondary Offering

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) saw its shares drop sharply on Tuesday after the company announced a secondary offering. Arena plans to offer 60 million shares of its common stock ...
Read Full Story »

FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte

Big Pharma and Big Biotech sometimes live and die by actions out of the U.S. Food and Drug Administration (FDA). For Eli Lilly and Co. (NYSE: LLY) and Incyte Corp. (NASDAQ: ...
Read Full Story »

Top Dividend Pharmaceutical Stocks Safe Bet for Rest of 2017

One thing that crept on the radar screen last week is that after eight years of a bull market, five of which are of the secular variety, after the S&P 500 ...
Read Full Story »

Short Sellers Run for Cover From Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Analysts Keep Stacking Up Higher Targets and Expectations for Eli Lilly

Eli Lilly and Co. (NYSE: LLY) is one of the better pharmaceutical stocks, as far as performers in 2017 top picks at JPMorgan. Its shares were last seen up 17% ...
Read Full Story »

OncoMed Hits All-Time Low After Failed Trial and Licensing Fallout

OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) saw its shares crumble after the company announced that Bayer Pharma is terminating its option agreement with the company, as well as a missed mid-stage ...
Read Full Story »

Biohaven Files for IPO

Biohaven Pharmaceutical Holding has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing but ...
Read Full Story »

Why the First Marijuana ETF May Pose Serious Problems for US Investors

With the explosive growth in medical and recreational marijuana in America, a slew of emerging companies have come public and brought new interest by investors in recent years. With there ...
Read Full Story »

Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) saw a handy gain on Friday after the company announced plans for the development of a late-stage trial. Specifically, Aurinia conducted discussions with ...
Read Full Story »

Is This the Turnaround Paratek Has Been Looking For?

Shares of Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial. Specifically, the firm reported ...
Read Full Story »

Cara Therapeutics Announces Pricing for Secondary Offering

Cara Therapeutics Inc. (NASDAQ: CARA) watched its shares slide as the week came to a close after the company reported that it had priced its secondary offering. The company has ...
Read Full Story »

How Akari Therapeutics Is Putting Itself on the Map

Shares of Akari Therapeutics PLC (NASDAQ: AKTX) saw a handy gain on Friday after the firm announced that the U.S. Food and Drug Administration (FDA) granted a Fast Track designation ...
Read Full Story »